Current Report Filing (8-k)
November 22 2021 - 09:05AM
Edgar (US Regulatory)
0000849636 false 0000849636 2021-11-17
2021-11-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
UNITED
STATES
SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C.
20549
FORM
8-K
Current
Report
Pursuant
to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported):
November 17, 2021
RESPIRERX PHARMACEUTICALS INC.
(Exact
name of registrant as specified in its charter)
|
Delaware |
|
1-16467 |
|
33-0303583 |
|
(State or
other jurisdiction
of
incorporation)
|
|
(Commission
File
Number)
|
|
(I.R.S
Employer
Identification
No.)
|
|
126 Valley Road,
Suite C
Glen Rock,
New Jersey
|
|
07452 |
|
(Address
of principal executive offices) |
|
(Zip
Code) |
Registrant’s
telephone number, including area code:
(201)
444-4947
(Former
name or former address, if changed since last
report.)
Check the
appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425) |
| |
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12) |
| |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b)) |
| |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
|
Title of
each class |
|
Trading
Symbol(s) |
|
Name of each
exchange on which registered |
| N/A |
|
N/A |
|
N/A |
Indicate by
check mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities act of 1933 (§230.405 of this
chapter) or Rule 12b-2 of the Securities Exchange Act of 1934
(§240.12b-2 of this chapter).
Emerging
growth company
☐
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01
Regulation FD Disclosure
On November
22, 2021, RespireRx Pharmaceuticals Inc. (the “Company”) announced
that a podcast interview hosted by the OTC Markets of the Company’s
Chief Executive Officer and President, Timothy Jones, recorded on
October 21, 2021, was made available to the general public on
November 17, 2021.
The
interview is part of the OTCQB, the OTC Venture Market, Podcast
series (Season 5, Episode 44), and appears on the OTC Markets
podcast page. A
link to the podcast will also be available on the Company’s
website, on Apple Podcasts, on Stitcher, and on Google Podcasts.
The podcast
has also been shared on the OTC Market’s below social media
channels
Twitter:
https://twitter.com/OTCMarkets/status/1461031918665883652?s=20
LinkedIn:
https://www.linkedin.com/feed/update/urn:li:activity:6866797613610520576
The press
release announcing the Podcast is attached as Exhibit
99.1.
Item 9.01
Financial Statements and Exhibits
(d)
Exhibits.
A list of
the exhibit that is furnished and not filed as part of this report
is set forth in the Exhibit Index, which is presented elsewhere in
this document, and is incorporated herein by reference.
EXHIBIT
INDEX
* Furnished
herewith.
Pursuant to
the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
| Date: November 22,
2021 |
RESPIRERX
PHARMACEUTICALS INC. |
|
|
|
|
|
|
By: |
/s/ Jeff
E. Margolis |
| |
|
Jeff E.
Margolis |
| |
|
Vice President,
Treasurer and Secretary |
RespireRx Pharmaceuticals (QB) (USOTC:RSPI)
Historical Stock Chart
From Apr 2022 to May 2022
RespireRx Pharmaceuticals (QB) (USOTC:RSPI)
Historical Stock Chart
From May 2021 to May 2022
